In a phase Ia/b trial that assessed the preliminary antitumor activity of ramucirumab (anti-VEGFR2 antibody) combined with pembrolizumab in NSCLC patients, 30% of the patients achieved an objective response, with a median PFS of 9.7 months and a median OS of 26.2 months (16). This evidence concerns the gene KDR and non-small cell lung carcinoma.